The Role of Interleukin-17A and Interleukin-17E in Multiple Myeloma Patients

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2011 Dec 31

PMID 22207110

Citations 14

Authors

Dorota Lemancewicz

Lukasz Bolkun

Ewa Jablonska

Ewa Czeczuga-Semeniuk

Agnieszka Kostur

Janusz Kloczko

Janusz Dzieciol

Affiliations

Soon will be listed here.

Abstract

Background: Tumor growth in multiple myeloma (MM) is regulated by the cytokine networks which are produced by myeloma cells and the microenvironment of the bone marrow. Interleukin-17 (IL-17) is implicated in the increased angiogenesis in the bone marrow of MM. Recent studies reported elevated levels of interleukin 17A (IL-17A) in the sera of patients with advanced stages according to Durie-Salmon classification.

Material/methods: We compared the concentration of IL-17A and IL-17E in the blood serum of 34 newly diagnosed MM patients with healthy subjects' sera. We also evaluated the concentration of IL-17A and IL-17E in the blood serum of MM patients and the relation to the percentage of plasma cells and other clinical parameters. The concentration of IL-17E and IL-17A of healthy subjects and patients with MM was assessed by enzyme-linked immunosorbent assay (ELISA).

Results: Our data confirm that IL-17A and IL-17E serum levels were significantly higher in all MM patients and also in patients with advanced stage compared with healthy subjects. We found the correlation between serum levels of IL-17A in MM patients and percentage of plasma cells. Our results also showed that if serum levels of IL-17E were higher in MM patients, the percentage of plasma cells and beta-2-microglobulin levels were lower.

Conclusions: The IL-17 family of cytokines may suppress or promote tumor growth. There seems to be some balance between the effects of IL-17A and IL-17E. The role of increased levels of IL-17E needs further investigation to understand its role in the pathobiology of MM.

Citing Articles

The IL-17 family in diseases: from bench to bedside.

Huangfu L, Li R, Huang Y, Wang S Signal Transduct Target Ther. 2023; 8(1):402.

PMID: 37816755 PMC: 10564932. DOI: 10.1038/s41392-023-01620-3.

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.

Maltby V, Xavier A, Ewing E, Campagna M, Sampangi S, Scott R Neurology. 2023; 101(7):e679-e689.

PMID: 37541839 PMC: 10437016. DOI: 10.1212/WNL.0000000000207489.

New insights into the function of Interleukin-25 in disease pathogenesis.

Yuan Q, Peng N, Xiao F, Shi X, Zhu B, Rui K Biomark Res. 2023; 11(1):36.

PMID: 37005677 PMC: 10068183. DOI: 10.1186/s40364-023-00474-9.

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients.

Dong M, Zhang J, Chen Q, He D, Yan H, Zheng G Front Oncol. 2022; 12:936670.

PMID: 36119497 PMC: 9471080. DOI: 10.3389/fonc.2022.936670.

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Zhaoyun L, Rong F Front Immunol. 2021; 12:663748.

PMID: 34290698 PMC: 8287504. DOI: 10.3389/fimmu.2021.663748.

References

Durie B, Salmon S, Finley P, Beckord J, Crowley J, Coltman C . Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990; 75(4):823-30. View

Kim M, Manoukian R, Yeh R, Silbiger S, Danilenko D, Scully S . Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood. 2002; 100(7):2330-40. DOI: 10.1182/blood-2002-01-0012. View

Garley M, Jablonska E, Grabowska S, Piotrowski L . IL-17 family cytokines in neutrophils of patients with oral epithelial squamous cell carcinoma. Neoplasma. 2009; 56(2):96-100. DOI: 10.4149/neo_2009_02_96. View

Moseley T, Haudenschild D, Rose L, Reddi A . Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003; 14(2):155-74. DOI: 10.1016/s1359-6101(03)00002-9. View

Prabhala R, Pelluru D, Fulciniti M, Prabhala H, Nanjappa P, Song W . Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010; 115(26):5385-92. PMC: 2902136. DOI: 10.1182/blood-2009-10-246660. View

Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A . Expression of Th-17 and RORγt mRNA in Behçet's Disease. Med Sci Monit. 2011; 17(4):CR227-34. PMC: 3539514. DOI: 10.12659/msm.881720. View

Dhodapkar K, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D . Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood. 2008; 112(7):2878-85. PMC: 2556623. DOI: 10.1182/blood-2008-03-143222. View

Broxmeyer H, Starnes T, Ramsey H, Cooper S, Dahl R, Williamson E . The IL-17 cytokine family members are inhibitors of human hematopoietic progenitor proliferation. Blood. 2006; 108(2):770. DOI: 10.1182/blood-2006-01-0292. View

Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R . Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001; 28(1):29-37. DOI: 10.1038/sj.bmt.1703093. View

10.

Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang S . IL-17 cytokine family. J Allergy Clin Immunol. 2004; 114(6):1265-73. DOI: 10.1016/j.jaci.2004.10.019. View

11.

Dimopoulos M, Barlogie B, Smith T, Alexanian R . High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991; 115(12):931-5. DOI: 10.7326/0003-4819-115-12-931. View

12.

Harrington L, Hatton R, Mangan P, Turner H, Murphy T, Murphy K . Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6(11):1123-32. DOI: 10.1038/ni1254. View

13.

Fort M, Cheung J, Yen D, Li J, Zurawski S, Lo S . IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2002; 15(6):985-95. DOI: 10.1016/s1074-7613(01)00243-6. View

14.

Yao Z, Fanslow W, Seldin M, Rousseau A, Painter S, Comeau M . Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995; 3(6):811-21. DOI: 10.1016/1074-7613(95)90070-5. View

15.

Alexandrakis M, Pappa C, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A . Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med. 2006; 17(6):412-6. DOI: 10.1016/j.ejim.2006.02.012. View

16.

Pappu B, Angkasekwinai P, Dong C . Regulatory mechanisms of helper T cell differentiation: new lessons learned from interleukin 17 family cytokines. Pharmacol Ther. 2008; 117(3):374-84. PMC: 2276145. DOI: 10.1016/j.pharmthera.2007.12.003. View

17.

Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman G, Borrello I . A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010; 116(18):3554-63. PMC: 4017298. DOI: 10.1182/blood-2010-05-283895. View

18.

Takahashi H, Numasaki M, Lotze M, Sasaki H . Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett. 2005; 98(2):189-93. DOI: 10.1016/j.imlet.2004.11.012. View